AI-powered drug discovery startup Isomorphic Labs, spun out of Google DeepMind and affiliated with Alphabet, is in early discussions to raise new funding, multiple outlets report. Bloomberg says the talks are at a valuation of at least $40 billion, while other coverage cites a broader target range. The reports do not specify the amount being raised or the timing of the round.
Isomorphic Labs, based in London, was formed in 2021 with the aim of commercialising DeepMind’s protein-folding work, including the AlphaFold model. The differing outlets mainly vary in how they describe the valuation figure—some frame it as at least $40 billion, while others point to potential valuation of up to $50 billion—rather than the basic premise of a fundraising effort. No sources in the provided articles confirm deal terms or whether the funding round will proceed.
